PT  - JOURNAL ARTICLE
AU  - Gomes, Claudia
AU  - Zuniga, Marisol
AU  - Crotty, Kelly A.
AU  - Qian, Kun
AU  - Lin, Lawrence Hsu
AU  - Argyropoulos, Kimon V.
AU  - Li, Huilin
AU  - Cotzia, Paolo
AU  - Rodriguez, Ana
TI  - Autoimmune anti-DNA antibodies predict disease severity in COVID-19 patients
AID  - 10.1101/2021.01.04.20249054
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.04.20249054
4099  - http://medrxiv.org/content/early/2021/01/04/2021.01.04.20249054.short
4100  - http://medrxiv.org/content/early/2021/01/04/2021.01.04.20249054.full
AB  - COVID-19 can lead to severe disease and death, however the mechanisms of pathogenesis in these patients remain poorly understood. High levels of autoimmune antibodies have been observed frequently in COVID-19 patients but their specific contribution to disease severity and clinical manifestations remain unknown.We performed a retrospective study of 115 COVID-19 hospitalized patients with different degrees of severity to analyze the generation of autoimmune antibodies to common antigens: a lysate of erythrocytes, the lipid phosphatidylserine (PS) and DNA.High levels of IgG autoantibodies against erythrocyte lysates were observed in a large percentage (up to 41%) of patients. Anti-DNA antibodies determined upon hospital admission correlated strongly with later development of severe disease, showing a positive predictive value of 89.5% and accounting for 22% of total severe cases. Statistical analysis identified strong correlations between anti-DNA antibodies and markers of cell injury, coagulation, neutrophil levels and erythrocyte size.Anti-DNA autoantibodies may play an important role in the pathogenesis of COVID-19 and could be developed as a predictive biomarker for disease severity and specific clinical manifestations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the NYU Langone COVID-19 special fund. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The collection of COVID-19 human biospecimens for research has been approved by NYULH Institutional Review Board under the S16-00122 Universal Mechanism of human bio-specimen collection and storage for research. This protocol allows the collection and analysis of clinical and demographic data. The database used for this project is de-identified.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available in the provided supplementary tables